Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Dengue is an arboviral disease caused by four distinct serotypes of dengue virus. The pathogenesis of dengue is not very clearly understood. Various pro- and anti-inflammatory cytokines are involved in the immune pathogenesis of dengue. Interleukin (IL)-2/IL-2 receptor interaction is supposed to play a protective role, while IL-4 acts as pro-inflammatory whereas IL-10 acts as anti-inflammatory cytokines. So far, not much information is available regarding the established role of these cytokines with dengue infection and severity.
Aims: our study aimed to show the association of IL-2, -4, and -10 with severity of dengue infection.
Settings And Design: This was a cross-sectional study.
Materials And Methods: The study was conducted in the year 2015; 150 blood samples from suspected dengue cases were confirmed for dengue and then with an equal number of healthy control samples were tested for cytokines levels (IL-2, -4, and -10) by ELISA. Severity of the dengue infection was determined on the basis of clinical manifestations based on the WHO criteria.
Statistical Analysis: for statistical analysis, SPSS version 21 (IBM, New York, United States) was used.
Results: Out of 150 samples, 56 samples came to be dengue positive. Thirty-eight (67.85%) cases were classified as nonsevere dengue and 18 (32.15%) were severe dengue. The serum levels of IL-4 and -10 were significantly raised in severe dengue cases as compared to nonsevere dengue cases. No significant association was observed between serum IL-2 levels and the severity of dengue.
Conclusion: IL-4 and -10 levels can be used as marker of severe dengue and help in early preparedness to start the treatment in the line of severe dengue.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/0377-4929.200027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trends in dengue incidence and lethality: interrupted time series analysis, Brazil, 2001-2022.
Epidemiol Serv Saude
September 2025
Universidade de Brasília, Faculdade de Medicina, Brasília, DF, Brazil.
Objective: To analyze the temporal trend of dengue incidence and lethality rates and the proportions of its serotypes, in the different macro-regions of Brazil, between 2001 and 2022. In particular, the immediate and gradual effects of these indicators were verified in the periods before and after the publication of the National Guidelines for the Prevention and Control of Dengue Epidemics.
Methods: This was an interrupted time series analysis.
The burden of dengue fever in travellers: a systematic literature review.
New Microbes New Infect
October 2025
Takeda Pharmaceuticals International AG, Zurich, Switzerland.
Background: Dengue is a mosquito-borne viral infection with growing global impact, including international travellers travelling to and from endemic regions. This systematic literature review aimed to assess the clinical and economic burden of dengue in travellers from non-endemic countries.
Methods: This systematic review was conducted following the PRISMA guidelines to assess the incidence, prevalence, mortality, healthcare resource use, and costs of dengue fever in travellers between non-endemic and endemic regions.
Dengue Virus Biosafety: An Analysis of Evidence, Global Inconsistencies, and Risk Gaps.
Appl Biosaf
August 2025
Mahidol-Oxford Tropical Research Medicine Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Introduction: Dengue virus (DENV) poses a significant global health threat, particularly in tropical and subtropical regions, where it is primarily transmitted by spp. mosquitoes. Its biosafety and biosecurity management present unique challenges due to both its vector-borne nature and rare instances of nonvector transmission.
View Article and Find Full Text PDFIdentification of multifunctional T-cell peptide epitopes for the development of DNA vaccines against dengue virus.
Hum Vaccin Immunother
December 2025
Beijing Institute of Tropical Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory for Research on Prevention and Treatment of Tropical Diseases, Beijing, China.
Dengue virus (DENV) is an important arthropod-borne virus that poses a global health threat, with half of the world's population at risk of infection. Currently, there is a lack of safe and effective vaccines for its prevention. Antibody-dependent enhancement (ADE) occurs when cross-reactive antibodies fail to neutralize heterologous DENV serotypes effectively, facilitating viral entry into Fc receptor-bearing cells and leading to more severe disease.
View Article and Find Full Text PDFDengue virus infection reprograms baseline innate immune gene expression.
Med
September 2025
Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore 169856, Singapore; Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore; Department of Clinical Translational Research, Singapore General Hospital, Singapo
Background: All three dengue vaccines that have completed phase 3 clinical trials have shown greater efficacy in dengue-seropositive compared to dengue-seronegative individuals. This includes the live-attenuated tetravalent dengue vaccine TAK-003, where immunogenicity in baseline seronegative individuals remains lower after two doses, despite seroconversion after the first dose, compared to baseline seropositive individuals after one dose.
Methods: A whole-genome microarray was used to analyze the host response to TAK-003.